Comparing Tolerability of Olanzapine in Schizophrenia and Affective Disorders

Moteshafi, Hoda; Zhornitsky, Simon; Brunelle, Sarah; Stip, Émmanuel

doi:10.1007/bf03261978

Cited by 22 publications

(7 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 44 In fact, previous works have highlighted different risk profiles of olanzapine for patients with different diagnoses; for example, weight gain is considered more prominent in patients with schizophrenia spectrum disorders compared to patients with affective disorders, 45 suggesting underlying mechanisms included differences in incidence of related lifestyle risk factors. 45 …”

Section: Discussionmentioning

confidence: 99%

Olanzapine‐associated dose‐dependent alterations for weight and metabolic parameters in a prospective cohort

Schoretsanitis

Dubath

Grosu

et al. 2022

Basic Clin Pharma Tox

View full text Add to dashboard Cite

Metabolic abnormalities have been associated with olanzapine treatment. We assessed if olanzapine has dose-dependent effects on metabolic parameters with changes for weight, blood pressure, lipid and glucose profiles being modelled using linear mixed-effects models. The risk of metabolic abnormalities including early weight gain (EWG) (≥5% during first month) was assessed using mixed-effects logistic regression models. In 392 olanzapine-treated patients (median age 38.0 years, interquartile range [IQR] = 26.0-53.3, median dose 10.0 mg/day, IQR = 5.0-10.0 for a median follow-up duration of 40.0 days, IQR = 20.7-112.2), weight gain was not associated with olanzapine dose (p = 0.61) although it was larger for doses versus ≤10 mg/day (2.54 AE 5.55 vs. 1.61 AE 4.51% respectively, p = 0.01). Treatment duration and co-

show abstract

Section: Discussionmentioning

confidence: 99%

Olanzapine‐associated dose‐dependent alterations for weight and metabolic parameters in a prospective cohort

Schoretsanitis

Dubath

Grosu

et al. 2022

Basic Clin Pharma Tox

View full text Add to dashboard Cite

show abstract

“…Pharmacogenetic studies already indicate a different genetic involvement in either first-episode psychosis patients or patients with chronic schizophrenia [124]. In this context it will be interesting to find out why, for example, schizophrenic patients are more likely to exhibit olanzapine-induced weight gain compared to bipolar patients [125].…”

Section: Future Directionsmentioning

confidence: 99%

Weight gain and antipsychotics: a drug safety review

Musil

Obermeier²,

Russ

et al. 2014

Expert Opinion on Drug Safety

153

111

View full text Add to dashboard Cite

Recently published data still support the hierarchical ranking of SGAs already proposed in previous reviews ranking clozapine and olanzapine as having the highest risk, followed by amisulpride, asenapine, iloperidone, paliperidone, quetiapine, risperidone and sertindole in the middle, and aripiprazole, lurasidone and ziprasidone with the lowest risk. Number needed to harm varied considerably in our meta-analysis. Younger patients and patients with a lower baseline body mass index are most vulnerable. The greatest amount of weight gain occurs within the first weeks of treatment. AIWG occurs in all diagnostic groups and is also common in treatment with first-generation antipsychotics; therefore, awareness of this adverse event is essential for anyone prescribing antipsychotics.

show abstract

“…As some adverse events might be more common among specific psychiatric disorders (e.g. metabolic disorders associated with schizophrenia (Moteshafi & Stip, ; Moteshafi et al ., ), suicide attempts with depression (Angst et al ., )), and patient characteristics indicate that quetiapine patients differ from users of the comparator drugs, HRs may be biassed because of residual confounding by indication. Furthermore, because of the missing indications for the majority of the patients, we could not reliably assess the relative adverse events rates across the different antipsychotics within specific indications.…”

Section: Discussionmentioning

confidence: 99%